tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Regeneron and Sanofi’s EoE Study: A Potential Market Game-Changer

Regeneron and Sanofi’s EoE Study: A Potential Market Game-Changer

Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Regeneron Pharmaceuticals and Sanofi are conducting a study titled A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT® As Standard of Care. This study aims to better understand the treatment of eosinophilic esophagitis (EoE) patients using DUPIXENT® (dupilumab) in standard care settings. The study’s significance lies in its potential to enhance understanding of EoE and inform future research and clinical decisions.

The intervention being tested is the drug dupilumab, marketed as DUPIXENT®. It is used to treat EoE by being prescribed as part of usual clinical practice, rather than being provided by the study sponsors.

This is an observational study with a cohort model and a prospective time perspective. It is designed to gather data over three years, focusing on how EoE affects patients’ quality of life and symptom progression.

The study began on November 22, 2024, with its primary completion and estimated completion dates yet to be determined. The last update was submitted on July 22, 2025, indicating ongoing recruitment and data collection.

For investors, this study could impact Regeneron and Sanofi’s stock performance by potentially expanding the market for DUPIXENT® if successful outcomes are reported. The study’s progress may influence investor sentiment positively, especially in the context of increasing demand for effective EoE treatments.

The study is currently ongoing, with further details available on the ClinicalTrials portal.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1